The estimated Net Worth of Fanny Cavalie is at least 777 千$ dollars as of 11 March 2024. Fanny Cavalie owns over 11,000 units of Foghorn Therapeutics stock worth over 704,446$ and over the last 2 years Fanny sold FHTX stock worth over 72,160$.
Fanny has made over 1 trades of the Foghorn Therapeutics stock since 2024, according to the Form 4 filled with the SEC. Most recently Fanny sold 11,000 units of FHTX stock worth 72,160$ on 11 March 2024.
The largest trade Fanny's ever made was selling 11,000 units of Foghorn Therapeutics stock on 11 March 2024 worth over 72,160$. On average, Fanny trades about 2,750 units every 0 days since 2023. As of 11 March 2024 Fanny still owns at least 75,992 units of Foghorn Therapeutics stock.
You can see the complete history of Fanny Cavalie stock trades at the bottom of the page.
Fanny's mailing address filed with the SEC is 500 TECHNOLOGY SQUARE, STE #700, CAMBRIDGE, MA, 02139.
Over the last 4 years, insiders at Foghorn Therapeutics have traded over 262,160$ worth of Foghorn Therapeutics stock and bought 305,500 units worth 4,888,000$ . The most active insiders traders include Adam Koppel、Ian F Smith、B Lynne Parshall. On average, Foghorn Therapeutics executives and independent directors trade stock every 109 days with the average trade being worth of 663,343$. The most recent stock trade was executed by Steven F. Bellon on 9 September 2024, trading 20,000 units of FHTX stock currently worth 190,000$.
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia; and FHD-609, a small molecule protein degrader of BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. Foghorn Therapeutics Inc. has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel therapeutics based on disruptors of a specified transcription factor target. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Foghorn Therapeutics executives and other stock owners filed with the SEC include: